摘要:
The present invention relates to the use of matrices in cell recruitment and the to modified matrices comprising homing factors for in vivo recellularisation of implantable medical devices such as cardiac valves and vascular grafts.
摘要:
For the treatment of an insufficient cardiac valve or a cardiac valve with a stenosis, a device is provided that comprises a micro axial pump (40). The pump portion (14) of the micro axial pump carries a dilating device (18) suitable for pushing open a stenosis in a valve. The dilating device is designed as a high-pressure balloon. During dilation, the micro axial pump (40) operates so that the heart is relieved. With insufficient cardiac valves, a stent (21) is fastened to the dilating device (17), the stent surrounding a flexible cardiac valve prosthesis (20). By dilation, the stent (21) is pressed against the insufficient cardiac valve and the same is passivated. The cardiac valve of the cardiac valve prosthesis is unfolded to assume the function of the natural cardiac valve.
摘要:
The present invention relates to an agent for reducing ischaemic damage to an organ, in particular to a heart and a brain, pharmaceutical compositions comprising said agent and the use of said agent for the treatment of ischaemic diseases to the heart and the brain. The agent comprises a substituted 4-phenyl-4-[1H-imidazol-2-yl]-piperidine derivative according to Formula (I) the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof, the N-oxide forms thereof and the prodrugs thereof. In particular are claimed the compounds according to Formula (I) in which A=B is C═O or SO2, X is a covalent bond, R1 is alkyloxy, alkyloxyalkyl, Ar or NR9R10, wherein R9 and R10 each independently are hydrogen or Ar; or A=B and R1 together form a benzoxazolyl radical; p is zero, R3 is benzyl optionally substituted with hydroxy, alkyl or alkyloxycarbonyl and R4 and R5 each are hydrogen. The use of said agents has important clinical ramifications with regard to the reduction of ischaemic damage to an organ in a mammal, in particular to a heart and/or a brain, the prevention of coronary artery diseases in a mammal by inducing a cardioprotective effect and the treatment and prevention of stroke.
摘要:
For the treatment of an insufficient cardiac valve or a cardiac valve with a stenosis, a device is provided that comprises a micro axial pump (40). The pump portion (14) of the micro axial pump carries a dilating device (18) suitable for pushing open a stenosis in a valve. The dilating device is designed as a high-pressure balloon. During dilation, the micro axial pump (40) operates so that the heart is relieved. With insufficient cardiac valves, a stent (21) is fastened to the dilating device (17), the stent surrounding a flexible cardiac valve prosthesis (20). By dilation, the stent (21) is pressed against the insufficient cardiac valve and the same is passivated. The cardiac valve of the cardiac valve prosthesis is unfolded to assume the function of the natural cardiac valve.
摘要:
For the treatment of an insufficient cardiac valve or a cardiac valve with a stenosis, a device is provided that comprises a micro axial pump (40). The pump portion (14) of the micro axial pump carries a dilating device (18) suitable for pushing open a stenosis in a valve. The dilating device is designed as a high-pressure balloon. During dilation, the micro axial pump (40) operates so that the heart is relieved. With insufficient cardiac valves, a stent (21) is fastened to the dilating device (17), the stent surrounding a flexible cardiac valve prosthesis (20). By dilation, the stent (21) is pressed against the insufficient cardiac valve and the same is passivated. The cardiac valve of the cardiac valve prosthesis is unfolded to assume the function of the natural cardiac valve.